Supernus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	776.83	718.95	661.82	607.52	667.24	579.78
Revenue Growth (YoY)	16.29%	8.63%	8.94%	-8.95%	15.09%	11.41%
Cost of Revenue	82.19	74.56	77.91	83.78	87.22	75.06
Gross Profit	694.64	644.39	583.91	523.74	580.02	504.71
Selling, General & Admin	520.79	485.56	321.58	336.36	377.22	304.76
Depreciation & Amortization Expenses	95.31	89.46	77.98	82.39	82.63	29.99
Research & Development	118.75	106.24	108.8	91.59	74.55	90.47
Other Operating Expenses	20.15	25.42	-6.11	18.67	-0.51	-6.53
Total Operating Expenses	755	706.67	502.25	529.01	533.89	418.69
Operating Income	-60.36	-62.28	81.67	-5.27	46.12	86.03
Total Non-Operating Income (Expense)	11.21	13.25	16.2	8.04	14.62	-12.85
Pretax Income	-49.15	-49.03	97.87	2.77	60.74	73.18
Provision for Income Taxes	-20.13	-10.48	24.01	1.45	0.03	19.75
Net Income	-29.02	-38.55	73.87	1.32	60.71	53.42
Net Income to Common	-29.02	-38.55	73.87	1.32	60.71	53.42
Net Income Growth	-	-	5512.84%	-97.83%	13.64%	-57.92%
Shares Outstanding (Basic)	57	56	55	55	54	53
Shares Outstanding (Diluted)	57	56	56	56	62	54
Shares Change (YoY)	1.84%	0.88%	0.81%	-10.01%	13.47%	1.24%
EPS (Basic)	-0.51	-0.68	1.34	0.02	1.13	1.01
EPS (Diluted)	-0.51	-0.68	1.32	0.02	1.04	0.98
EPS Growth	-	-	6500.00%	-98.08%	6.12%	-58.48%
Shares Outstanding	58.04	57.46	55.74	54.72	54.25	53.26
Free Cash Flow	82.25	45.99	171.23	110.53	116.41	125.08
Free Cash Flow Growth	78.82%	-73.14%	54.91%	-5.05%	-6.93%	-7.15%
Free Cash Flow Per Share	1.44	0.81	3.06	1.99	1.89	2.30
Gross Margin	89.42%	89.63%	88.23%	86.21%	86.93%	87.05%
Operating Margin	-7.77%	-8.66%	12.34%	-0.87%	6.91%	14.84%
Profit Margin	-3.74%	-5.36%	11.16%	0.22%	9.10%	9.21%
FCF Margin	10.59%	6.40%	25.87%	18.19%	17.45%	21.57%
EBITDA	36.95	29.28	162.08	79.59	131.67	118.62
EBITDA Margin	4.76%	4.07%	24.49%	13.10%	19.73%	20.46%
EBIT	-60.36	-62.28	81.67	-5.27	46.12	86.03
EBIT Margin	-7.77%	-8.66%	12.34%	-0.87%	6.91%	14.84%
Effective Tax Rate	40.96%	21.37%	24.53%	52.47%	0.05%	26.99%

Updated May 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q